Search results
Results from the WOW.Com Content Network
The company didn't quite meet expectations for either trailing results or full-year guidance.
On Friday, FDA's Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) did not provide sufficient evidence to conclude that omburtamab improves ...
NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results ...
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results ...
The latest analyst coverage could presage a bad day for Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ), with the analysts...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced strategic ...
Y-mAbs Therapeutics, Inc. Property: ANSCOR Property Holdings, Inc. Seven Seas Resorts and Leisure, Inc. (Amanpulo Resort) KSA Realty Corporation (The Enterprise Center)
For premium support please call: 800-290-4726 more ways to reach us